0RAD Stock Chart & Stats
€3.19
-€0.53(-6.99%)
At close: 4:00 PM EST
€3.19
-€0.53(-6.99%)
Day’s Range― - ―
52-Week Range€2.10 - €7.19
Previous CloseN/A
Volume90.00
Average Volume (3M)1.04K
Market Cap
€51.15M
Enterprise Value€128.21
Total Cash (Recent Filing)€22.65M
Total Debt (Recent Filing)€35.38M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding23,560,110
10 Day Avg. Volume1,012
30 Day Avg. Volume1,043
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.20
Price to Sales (P/S)43.87
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.13
Revenue Forecast (FY)€2.35M
Bulls Say, Bears Say
Bulls Say
Focused Immunotherapy PipelineA focused immunotherapy portfolio gives OSE exposure to markets where differentiated immune modulation can support meaningful clinical value. Its work across oncology and immune-inflammatory diseases, combined with preclinical and clinical programs, provides multiple avenues for future development and partnering.
Prior Cash GenerationThe strong positive operating and free cash flow reported in 2024 shows that the business has previously demonstrated the capacity to generate substantial cash. Although performance was not sustained in 2025, this history provides evidence of potential financial operating leverage when revenue and profitability improve.
Improved Leverage Versus 2023Leverage has improved from the more pressured 2023 position, indicating some progress in the balance-sheet structure over the longer comparison period. This relative improvement can support financial resilience, although current debt still exceeds equity and requires disciplined capital management.
Bears Say
Severe Revenue VolatilityThe sharp contraction from 2024 revenue to a very small 2025 base demonstrates that OSE's reported revenue stream is highly volatile and difficult to predict. Such inconsistency can make investment in research programs harder to sustain and increases reliance on successful future development milestones.
Return To Heavy LossesThe return to a substantial net loss after 2024 profitability signals that earnings power is not yet durable. Persistent operating losses could erode the capital base, constrain investment in the pipeline, and increase the importance of securing commercial, partnering, or financing support.
Significant Cash BurnThe reversal from approximately €48.4M of positive free cash flow in 2024 to more than €34M of cash burn in 2025 materially weakens internal funding capacity. Continued burn would increase funding dependency and could limit strategic flexibility while clinical development continues.
OSE Immunotherapeutics SA News
0RAD FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest share price was €2.10 and its highest was €7.18 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is €51.15M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
OSE Immunotherapeutics SA’s upcoming earnings report date is Mar 31, 2027 which is in 179 days.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Apr 30, 2026. The company reported -€1.007 earnings per share for the quarter.
Is OSE Immunotherapeutics SA overvalued?
According to Wall Street analysts OSE Immunotherapeutics SA’s price is currently Overvalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 23,560,110 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -€1.007 in its last earnings report. Following the earnings report the stock price went down -4.5%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in GB:0RAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OSE Immunotherapeutics SA
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.